Retractable Technologies, Inc. Announces Litigation Updates (3/21/17)
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE MKT: RVP) announced today that the U.S. Supreme Court denied its petition for a writ of certiorari to review the December 2, 2016 Fifth Circuit Court of Appeals decision in its case against Becton, Dickinson and Company (“BD”). The Fifth Circuit Court of Appeals decision had remanded the case against BD to the Eastern District of Texas for a redetermination as to the amount of damages to which Retractable is entitled. On March 17, 2017, the Eastern District of Texas set the date for the one-day bench trial for May 11, 2017 in Sherman, Texas.
Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with Luer lock syringes, Luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle can also be used to aspirate fluids and collect blood. Retractable's products are distributed by various specialty and general line distributors. For more information on Retractable, visit its website at www.retractable.com.
News 
Market Data 
Discover 
